Search Results
FT596: iPSC-derived CAR-NK cells with engineered persistence for B-cell malignancies
Engineered iPSC-derived Lymphocytes for Improved Cancer Therapy
FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell
Dan Kaufman - iPSC Derived NKs: Targeting Cancer with an Engineered, iPSC-Derived NK Cell
Novel multi-antigen targeted CAR-NK cell for the treatment of B cell malignancies
Updates on iPSC-derived NK cells for the treatment of glioblastoma
Novel off-the-shelf CAR NK product is potent, persistent and overcomes CD19 antigen escape
TGFb-resistant NK cells for hematological malignancies
CAR-NKs for B cell malignancies
Future prospects for NK cell therapy
Update on CAR-NK cell therapy work at MD Anderson
Clinical Development of NK Cell Cancer Therapy
